02/11/2017
Zealand reports royalty revenue for the third quarter of 2017
Zealand Pharma (“Zealand”) reports Q3 2017 royalty revenue from Sanofi’s sales of Lyxumia®/Adlyxin® (lixisenatide) of DKK 5.0 million/USD 0.8 million and from Suliqua®/Soliqua® 100/33 of DKK 5.4 million/USD 0.9 million [...]
